<div id="readability-page-1"><div id="ctl00_CPI_dvBody"><div><div><p>Add <img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/> as your preferred news source on Google</p><div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/> Add Now</p></div></div></div><p> Gilead Sciences, Inc. (GILD) announced Tuesday positive results from a Phase 3 study in people with primary biliary cholangitis (PBC), showing that treatment with Livdelzi (seladelpar) led to significantly more patients achieving normalization of alkaline phosphatase (ALP).</p><p>ALP is a key liver marker of disease progression, compared with placebo after 52 weeks. The primary endpoint was defined as a composite of ALP = 1.0× upper limit of normal (ULN) and a = 15% decrease from baseline.</p><p>These findings were observed in people with inadequately controlled disease, defined as having ALP levels above the ULN and below 1.67×ULN, with an incomplete response or intolerance to ursodeoxycholic acid (UDCA).</p><p>The safety profile of seladelpar observed in IDEAL was consistent with previously reported Livdelzi studies, with no new safety concerns identified.</p><p>In PBC, ALP is a key disease marker associated with disease activity and long-term outcomes. ALP levels above normal, including in the 1.0 to 1.67×ULN range, are associated with increased risk of progression to liver transplant or death compared with normalized ALP levels. </p><p>For comments and feedback contact: editorial@rttnews.com</p><p>Business News</p></div></div>

GILD

<p>Gilead Sciences announced positive Phase 3 results for Livdelzi (seladelpar) in treating primary biliary cholangitis. The study showed significantly more patients achieved normalization of alkaline phosphatase (ALP), a key liver marker, compared to placebo after 52 weeks. The safety profile remained consistent with previous studies, with no new concerns identified.</p>

Gilead Sciences Reports Positive Results From Phase 3 Study Of Livdelzi For Biliary Cholangitis